Vittorio E Andreucci
Overview
Explore the profile of Vittorio E Andreucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Tentori F, Wang M, Bieber B, Karaboyas A, Li Y, Jacobson S, et al.
Clin J Am Soc Nephrol
. 2014 Dec;
10(1):98-109.
PMID: 25516917
Background And Objectives: Elevated parathyroid hormone levels may be associated with adverse clinical outcomes in patients on dialysis. After the introduction of practice guidelines suggesting higher parathyroid hormone targets than...
3.
Esposito P, Balducci A, Andreucci V
J Nephrol
. 2013 Sep;
26(5):949-52.
PMID: 24052467
No abstract available.
4.
Kawaguchi T, Karaboyas A, Robinson B, Li Y, Fukuhara S, Bieber B, et al.
J Am Soc Nephrol
. 2013 Jul;
24(9):1493-502.
PMID: 23886592
It is unknown whether regular patient-doctor contact (PDC) contributes to better outcomes for patients undergoing hemodialysis. Here, we analyzed the associations between frequency and duration of PDC during hemodialysis treatments...
5.
Neri L, Martini A, Andreucci V, Gallieni M, Rocca Rey L, Brancaccio D
Am J Nephrol
. 2011 Jun;
34(1):71-6.
PMID: 21677429
Objectives: Poor medication adherence is common in end-stage renal disease and may cause suboptimal outcomes and increased healthcare costs. We assessed the association between regimen complexity, perceived burden of oral...
6.
7.
Mazzaferro S, Brancaccio D, Messa P, Andreucci V, Bellinghieri G, Bigazzi R, et al.
J Nephrol
. 2010 Dec;
24(2):225-35.
PMID: 21188680
Aims: In recent years, treatment options for secondary hyperparathyroidism (SHPT) have increased (e.g., paricalcitol, calcimimetics). To determine the impact these new treatments have on achieving K/DOQI targets, an observational, prospective...
8.
Galassi A, Brancaccio D, Andreucci V
J Nephrol
. 2010 Nov;
23(6):743-6.
PMID: 21046539
No abstract available.
9.
Andreucci V
G Ital Nefrol
. 2010 Jul;
27(4):409-16.
PMID: 20672240
The contribution of Italians to the development of nephrology has been very important but not always recognized. Thus, historical accounts do not mention the fact that the concept of short...
10.
Memoli B, Salerno S, Procino A, Postiglione L, Morelli S, Sirico M, et al.
Clin Sci (Lond)
. 2010 Apr;
119(4):163-74.
PMID: 20380647
Inflammation plays a key role in the progression of cardiovascular disease, the leading cause of mortality in ESRD (end-stage renal disease). Over recent years, inflammation has been greatly reduced with...